| LEGEND BIOTECH SP.ADS/2 |
| USA |
| Gesundheit |
| US52490G1022 / A2P5AH |
| 9LB (Frankfurt) / LEGN (NASDAQ) |
| FRA:9LB, ETR:9LB, 9LB:GR, NASDAQ:LEGN |
| - |
| https://www.legendbiotech.. |
|
Legend Biotech Corporation develops, manufactures, and commercializes chimeric antigen receptor T-cell (CAR-T) therapies for oncology and other serious diseases. The company's flagship product is CARVYKTI, a BCMA-targeted CAR-T cell therapy for relap..
>Volltext.. |
| 5759.61 Mio. EUR |
| 5374.64 Mio. EUR |
| 987.57 Mio. EUR |
| -80.03 Mio. EUR |
| -216.97 Mio. EUR |
| -1.18 EUR |
| 336.55 Mio. EUR |
| 558.82 Mio. EUR |
| -151.64 Mio. EUR |
| 1.64 |
| 56.7% |
| -14.4% |
| - |
| - |
| - |
| - |
| LEGEND BIOTECH |
| 14.06.26 |
|